Virologic Outcome After Switching From a Nucleoside Reverse Transcriptase Inhibitor to Tenofovir in Patients With Undetectable HIV-1 RNA Plasma Level
- 1 July 2004
- journal article
- research article
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 36 (3) , 876-878
- https://doi.org/10.1097/00126334-200407010-00016
Abstract
No abstract availableThis publication has 5 references indexed in Scilit:
- Change to abacavir-lamivudine-tenofovir combination treatment in patients with HIV-1 who had complete virological suppressionThe Lancet, 2003
- Substitution of Nevirapine, Efavirenz, or Abacavir for Protease Inhibitors in Patients with Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 2003
- Determining the antiviral activity of tenofovir disoproxil fumarate in treatment-naive chronically HIV-1-infected individualsAIDS, 2003
- Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind studyAIDS, 2002
- A Randomized Trial of Simplified Maintenance Therapy with Abacavir, Lamivudine, and Zidovudine in Human Immunodeficiency Virus InfectionThe Journal of Infectious Diseases, 2002